Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin

Antofloxacin (AFX) is a novel fluoroquinolone that has been approved in China for the treatment of infections caused by a variety of bacterial species. We investigated whether it could be repurposed for the treatment of tuberculosis by studying its in vitro activity. We determined the wild-type and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xia, Wang, Guirong, Chen, Suting, Wei, Guomei, Shang, Yuanyuan, Dong, Lingling, Schön, Thomas, Moradigaravand, Danesh, Parkhill, Julian, Peacock, Sharon J., Köser, Claudio U., Huang, Hairong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Mechanisms of Resistance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997829/
https://www.ncbi.nlm.nih.gov/pubmed/27324769
http://dx.doi.org/10.1128/AAC.00393-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997829/
https://www.ncbi.nlm.nih.gov/pubmed/27324769
http://dx.doi.org/10.1128/AAC.00393-16

Ejemplares similares